ACADIA Pharmaceuticals Inc. Stock News

Acadia Pharmaceuticals shows fiscal resilience with a shift to net positive income, buoyed by Daybue's strong Q2 debut and increased Nuplazid sales. Daybue targets a high-need area in Rett syndrome, s

Baker Bros. Advisors has been steadily buying Acadia Pharmaceuticals and Roivant Sciences this year.

Not many stocks can beat the broader market over the long haul. Acadia Pharmaceuticals, a central nervous disorder specialist, may have what it takes.

Developmental biotechs can deliver outstanding returns for risk-tolerant investors. Wall Street is exceptionally bullish on Stoke Therapeutics, a clinical-stage company developing RNA-based medicines.

After losing some value lately, a hammer chart pattern has been formed for Acadia (ACAD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revision

FATE reports a lower-than-expected loss on a decline in operating expenses in the second quarter of 2023.

Acadia (ACAD) reports better-than-expected second-quarter 2023 results, raising its financial guidance for the year. The company also provides updates on its pipeline.

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. This compares to loss of $0.21 per share a year ag

We expect GSK's specialty products like Cabenuva, Dovato, Bexsero, Breo Ellipta and Shingrix to drive second-quarter sales performance.

Shares of ACADIA Pharmaceuticals Inc. NASDAQ: ACAD jumped nearly 25% on Friday after the San Diego-based company announced preliminary second-quarter results and a pivotal acquisition. The gain was th

In a stunning two-day rally, shares of Acadia Pharmaceuticals  (US:ACAD) have seen a 16% surge following the announcement of the company's acquisition of expanded commercial rights for the groundbre

Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the

Acadia has acquired expanded rights to two drugs. The company also provided encouraging preliminary Q2 sales figures for its two approved products.

Acadia (ACAD) rises 23% for extending its existing licensing agreement with Neuren to include ex-North American rights to trofinetide along with the global rights to a different developmental candidat

Stock markets kept climbing on Thursday. Acadia stock moved higher as the company expanded a key licensing agreement.